These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

358 related items for PubMed ID: 17291993

  • 21. Cholesterol oxides as biomarkers of oxidative stress in type 1 and type 2 diabetes mellitus.
    Ferderbar S, Pereira EC, Apolinário E, Bertolami MC, Faludi A, Monte O, Calliari LE, Sales JE, Gagliardi AR, Xavier HT, Abdalla DS.
    Diabetes Metab Res Rev; 2007 Jan; 23(1):35-42. PubMed ID: 16634125
    [Abstract] [Full Text] [Related]

  • 22. Targeting vascular risk in patients with metabolic syndrome but without diabetes.
    Athyros VG, Mikhailidis DP, Papageorgiou AA, Didangelos TP, Peletidou A, Kleta D, Karagiannis A, Kakafika AI, Tziomalos K, Elisaf M.
    Metabolism; 2005 Aug; 54(8):1065-74. PubMed ID: 16092057
    [Abstract] [Full Text] [Related]

  • 23. Effects of fenofibrate on plasma cytokine concentrations in patients with atherosclerosis and hyperlipoproteinemia IIb.
    Madej A, Okopien B, Kowalski J, Zielinski M, Wysocki J, Szygula B, Kalina Z, Herman ZS.
    Int J Clin Pharmacol Ther; 1998 Jun; 36(6):345-9. PubMed ID: 9660044
    [Abstract] [Full Text] [Related]

  • 24. Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
    Alrasadi K, Awan Z, Alwaili K, Ruel I, Hafiane A, Krimbou L, Genest J.
    Am J Cardiol; 2008 Nov 15; 102(10):1341-7. PubMed ID: 18993152
    [Abstract] [Full Text] [Related]

  • 25. Effects of atorvastatin on the clearance of triglyceride-rich lipoproteins in familial combined hyperlipidemia.
    Castro Cabezas M, Verseyden C, Meijssen S, Jansen H, Erkelens DW.
    J Clin Endocrinol Metab; 2004 Dec 15; 89(12):5972-80. PubMed ID: 15579746
    [Abstract] [Full Text] [Related]

  • 26. Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.
    Cenarro A, Artieda M, Gonzalvo C, Meriño-Ibarra E, Arístegui R, Gañán A, Díaz C, Sol JM, Pocoví M, Civeira F, ATOMIX Study Group.
    Am Heart J; 2005 Dec 15; 150(6):1154-62. PubMed ID: 16338252
    [Abstract] [Full Text] [Related]

  • 27. Bile acid synthesis precursors in familial combined hyperlipidemia: the oxysterols 24S-hydroxycholesterol and 27-hydroxycholesterol.
    Baila-Rueda L, Mateo-Gallego R, Jarauta E, de Castro-Orós I, Bea AM, Cenarro A, Civeira F.
    Biochem Biophys Res Commun; 2014 Apr 11; 446(3):731-5. PubMed ID: 24406166
    [Abstract] [Full Text] [Related]

  • 28. Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia.
    Melenovsky V, Malik J, Wichterle D, Simek J, Pisarikova A, Skrha J, Poledne R, Stavek P, Ceska R.
    Am Heart J; 2002 Oct 11; 144(4):E6. PubMed ID: 12360175
    [Abstract] [Full Text] [Related]

  • 29. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
    Buldak L, Dulawa-Buldak A, Labuzek K, Okopien B.
    Int J Clin Pharmacol Ther; 2012 Nov 11; 50(11):805-13. PubMed ID: 22943927
    [Abstract] [Full Text] [Related]

  • 30. Effects of atorvastatin on fasting plasma and marginated apolipoproteins B48 and B100 in large, triglyceride-rich lipoproteins in familial combined hyperlipidemia.
    Verseyden C, Meijssen S, Cabezas MC.
    J Clin Endocrinol Metab; 2004 Oct 11; 89(10):5021-9. PubMed ID: 15472200
    [Abstract] [Full Text] [Related]

  • 31. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S.
    Clin Ther; 2008 Jun 11; 30(6):1089-101. PubMed ID: 18640465
    [Abstract] [Full Text] [Related]

  • 32. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.
    Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW.
    Diabetes Care; 2007 Aug 11; 30(8):1945-51. PubMed ID: 17483155
    [Abstract] [Full Text] [Related]

  • 33. Vitamin E supplementation in patients with carotid atherosclerosis: reversal of altered oxidative stress status in plasma but not in plaque.
    Micheletta F, Natoli S, Misuraca M, Sbarigia E, Diczfalusy U, Iuliano L.
    Arterioscler Thromb Vasc Biol; 2004 Jan 11; 24(1):136-40. PubMed ID: 14592846
    [Abstract] [Full Text] [Related]

  • 34. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R, Varadharajan S, Kathale A, Nagraj LM, Periyandavar I, Nayak UP, Sharma A, Bolmall C, Baliga VP.
    J Indian Med Assoc; 2008 Jul 11; 106(7):464-7. PubMed ID: 18975505
    [Abstract] [Full Text] [Related]

  • 35. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
    Tonstad S, Retterstøl K, Ose L, Ohman KP, Lindberg MB, Svensson M.
    Metabolism; 2007 Sep 11; 56(9):1285-92. PubMed ID: 17697874
    [Abstract] [Full Text] [Related]

  • 36. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
    Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagné C, Couture P.
    Metabolism; 2008 Feb 11; 57(2):246-54. PubMed ID: 18191056
    [Abstract] [Full Text] [Related]

  • 37. Tumor necrosis factor-alpha is a marker of familial combined hyperlipidemia, independently of metabolic syndrome.
    Pauciullo P, Gentile M, Marotta G, Baiano A, Ubaldi S, Jossa F, Iannuzzo G, Faccenda F, Panico S, Rubba P.
    Metabolism; 2008 Apr 11; 57(4):563-8. PubMed ID: 18328361
    [Abstract] [Full Text] [Related]

  • 38. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
    McKenney JM, Farnier M, Lo KW, Bays HE, Perevozkaya I, Carlson G, Davies MJ, Mitchel YB, Gumbiner B.
    J Am Coll Cardiol; 2006 Apr 18; 47(8):1584-7. PubMed ID: 16630994
    [Abstract] [Full Text] [Related]

  • 39. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.
    Wu TJ, Ou HY, Chou CW, Hsiao SH, Lin CY, Kao PC.
    Ann Clin Lab Sci; 2007 Apr 18; 37(2):158-66. PubMed ID: 17522372
    [Abstract] [Full Text] [Related]

  • 40. Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment.
    Stulc T, Malbohan I, Malík J, Fialová L, Soukupová J, Ceska R.
    Am Heart J; 2003 Dec 18; 146(6):E21. PubMed ID: 14661010
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.